Summary:
Seegene Inc. showcased its high-precision HPV screening and genotyping solutions at EUROGIN 2025, emphasizing the importance of accurate detection for cervical cancer prevention.

Takeaways:

  1. Advanced HPV Diagnostics – Seegene’s solutions enhance the accurate identification of high-risk HPV types crucial for cervical cancer detection.
  2. Integration into Clinical Practice – Experts discussed real-world implementation, highlighting the benefits of self-sampling for broader HPV screening adoption.
  3. Commitment to Prevention – Seegene’s continued participation in global forums underscores its dedication to improving HPV diagnostics and supporting WHO’s cervical cancer elimination goals.

Seegene Inc., a global provider of a total solution for PCR molecular diagnostics, presented its high-precision HPV screening and full genotyping solutions at the recent European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2025 in Porto, Portugal.

Accurate HPV Screening Emphasized

The company showcased its expertise through an exhibition booth under the theme “Elevating Confidence in HPV Screening” and hosted symposium programs to emphasize accurate identification of high-risk HPV types related to cervical cancer is critical. Seegene’s advanced solution enhances diagnostic accuracy, enabling timely, and effective detection.

Seegene presented its flagship HPV diagnostic product lineup that are designed to simultaneously detect HPV genotypes responsible for cervical cancer and/or HPV-related cancer. This capability is crucial in identifying high-risk HPV types that are known to cause cervical cancer and detecting other genotypes that are associated with benign tumors.

Integrating into Real-World Practice

At the Seegene symposium on March 16, leading clinical experts from Europe discussed strategies for integrating HPV testing into real-world clinical practice. The symposium underscored the critical role of HPV testing in the early detection of cervical cancer. Additionally, the experts highlighted the advantages of self-sampling, a method that enables individuals to collect their own samples. This approach not only streamlines the testing process but also promotes the broader adoption of HPV screening.

“Seegene’s HPV testing solutions are designed to deliver accurate diagnostics and reliable testing capabilities in real-world clinical environments,” says Daniel Shin, executive vice president and chief global sales & marketing officer at Seegene.

Commitment to HPV Screening

Seegene’s annual participation in EUROGIN is a testament to its commitment to advancing HPV screening and genotyping for the accurate diagnosis and prevention of cervical cancer. In July 2024, the company also took part in the Asia-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) 2024 held in Seoul.

According to the World Health Organization (WHO), cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of cancer-related deaths. In 2018, the WHO launched the 90-70-90 campaign to eliminate cervical cancer. The targets aim to achieve 90% HPV vaccination coverage among girls by the age of 15; 70% of women screened using high-performance tests by the age of 35 and 45; and treatment for 90% of women identified with pre-cancer and invasive cancer by 2030.

Featured Image: Seegene showcases its flagship HPV diagnostic product lineup and presents its HPV genotyping solution at EUROGIN 2025 in Portugal from March 16-19 (CET). Photo: Seegene